MedTrace Logo

Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study

NCT04707326 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2040

Last updated 2024-12-20

Study results available
· View outcomes & findings →

Summary

This study aims to determine real-life clinical efficacy of virally suppressed patienst switching to DTG/3TC compared to DTG triple drug cART controls

Conditions

Interventions

DRUG

Dolutegravir / Lamivudine Pill

HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B

Sponsors & Collaborators

  • Maasstad Hospital

    collaborator OTHER

  • Haaglanden Medical Centre

    collaborator OTHER

  • Catharina Ziekenhuis Eindhoven

    collaborator OTHER

  • Elisabeth-TweeSteden Ziekenhuis

    collaborator OTHER

  • Rijnstate Hospital

    collaborator OTHER

  • Admiraal de Ruyter Hospital

    collaborator OTHER

  • Spaarne Gasthuis

    collaborator OTHER

  • Medisch Spectrum Twente

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2023-11-01
Completion
2026-11-01
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04707326 on ClinicalTrials.gov